Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Operating Income : $-123.4 Mil (TTM As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Arcturus Therapeutics Holdings Operating Income?

Arcturus Therapeutics Holdings's Operating Income for the three months ended in Mar. 2024 was $-30.4 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-123.4 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Arcturus Therapeutics Holdings's Operating Income for the three months ended in Mar. 2024 was $-30.4 Mil. Arcturus Therapeutics Holdings's Revenue for the three months ended in Mar. 2024 was $32.6 Mil. Therefore, Arcturus Therapeutics Holdings's Operating Margin % for the quarter that ended in Mar. 2024 was -93.29%.

Arcturus Therapeutics Holdings's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Arcturus Therapeutics Holdings's annualized ROC % for the quarter that ended in Mar. 2024 was -101.97%. Arcturus Therapeutics Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -213.71%.

Arcturus Therapeutics Holdings Operating Income Historical Data

The historical data trend for Arcturus Therapeutics Holdings's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcturus Therapeutics Holdings Operating Income Chart

Arcturus Therapeutics Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Income

Get a 7-Day Free Trial

-25.51

-71.52

-202.85

12.18

-78.21

Arcturus Therapeutics Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Income	Get a 7-Day Free Trial															14.76	-55.37	-19.31	-18.27	-30.41

Arcturus Therapeutics Holdings Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-123.4 Mil.

Arcturus Therapeutics Holdings (NAS:ARCT) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Arcturus Therapeutics Holdings's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-121.648 * ( 1 - -1.39% )	/	( (112.978	+	128.942)	/ 2 )
=	-123.3389072	/	120.96
=	-101.97 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	429.402	-	24.419	-	( 292.005	-	max(0, 81.989	-	386.59	+	292.005	))
=	112.978

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	418.849	-	29.549	-	( 288.396	-	max(0, 115.43	-	375.788	+	288.396	))
=	128.942

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Arcturus Therapeutics Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-105.796	/	( ( (40.927 + max(16.905, 0))	+	(41.176 + max(-23.768, 0)) )	/	2 )
=	-105.796	/	( ( 57.832	+	41.176 )	/	2 )
=	-105.796	/	49.504
=	-213.71 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(32.064	+	0	+	62.521)	-	(24.419	+	47.343	+	5.918)
=	16.905

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(27.057	+	0	+	60.335)	-	(29.549	+	74.509	+	7.102)
=	-23.768

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Arcturus Therapeutics Holdings's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %	=	Operating Income (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-30.412	/	32.598
	=	-93.29 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Arcturus Therapeutics Holdings Operating Income Related Terms

Thank you for viewing the detailed overview of Arcturus Therapeutics Holdings's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcturus Therapeutics Holdings Inc (NAS:ARCT) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

10628 Science Center Drive, Suite 250, San Diego, CA, USA, 92121

Website

https://www.arcturusrx.com

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.

Executives

Pad Chivukula	officer: Chief Scientific Officer & COO	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Keith C Kummerfeld	officer: See Remarks	10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Magda Marquet	director	ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
John Markels	director	C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
Joseph E Payne	director, 10 percent owner, officer: President and CEO	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Jing L. Marantz	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Ultragenyx Pharmaceutical Inc.	director, 10 percent owner	60 LEVERONI COURT, NOVATO CA 94949
Lance Kurata	officer: Chief Legal Officer	10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Andy Sassine	officer: Chief Financial Officer	82 DEVONSHIRE STREET, BOSTON MA 02109
Steven George Hughes	officer: Chief Development Officer	6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
James F Barlow	director	2525 DUPONT DR, IRVINE CA 92612
Edward W Holmes	director	C/O TULARIK INC, TWO CORP DRIVE SOUTH, SAN FRANCISCO CA 8608257208
Peter C Farrell	director	RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Karah Herdman Parschauer	director	60 LEVERONI COURT, NOVATO CA 94949